Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Oriola Q2’24: Sales growth in both segments

By Rauli JuvaAnalyst
Oriola

Oriola’s Q2 earnings were quite in line with our estimates and the guidance for the whole year of 2024 remained unchanged. The joint venture company in Sweden performed better than we expected after two very weak quarters. CEO Katarina Gabrielson comments on the Q2 result in this interview. 

Content:
00:00 Intro
00:09 Prohibited sale of Svensk dos AB
01:33 Q2 highlights
02:18 Growth in sales and invoicing
03:00 Joint venture company in Sweden
04:23 Outlook for dose dispensing business in Sweden

Stay up to date
Company management interviews

Recent videos

HCA Morgenbørs 08/12 - Små fald i futures og fokus på Gubra, Genmab og Lundbeck
08.12.2025, 09.24 Genmab
AKTIER MED FRIIS - UGE 49 2025
05.12.2025, 12.00
HCA Morgenbørs 05/12 - Overvejende positive futures-markeder hvor kun Japan er i minus
05.12.2025, 09.20 GreenMobility
GreenMobility: What is the investment case in driverless cars
05.12.2025, 08.00 GreenMobility
UPM and Sappi are planning a joint venture in graphic papers
04.12.2025, 13.00 UPM-Kymmene
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.